Similarly, cells with low‐level expression of MCL1, such as DLD1 colon cancer cells, or cells where MCL1 levels were reduced by RNAi are highly sensitive to BCLX inhibitors when combined with mitotic drivers, such as the Aurora B inhibitor ZM447439 10, 86. This evidence concerns the gene MCL1 and colonic neoplasm.